CO5580794A2 - Conjugados de hormona de crecimiento humana modificada quimicamente - Google Patents

Conjugados de hormona de crecimiento humana modificada quimicamente

Info

Publication number
CO5580794A2
CO5580794A2 CO04046633A CO04046633A CO5580794A2 CO 5580794 A2 CO5580794 A2 CO 5580794A2 CO 04046633 A CO04046633 A CO 04046633A CO 04046633 A CO04046633 A CO 04046633A CO 5580794 A2 CO5580794 A2 CO 5580794A2
Authority
CO
Colombia
Prior art keywords
conjugate
poly
amino acid
ethylene glycol
molecule
Prior art date
Application number
CO04046633A
Other languages
English (en)
Inventor
F Finn Roy
Liao Wei
R Siegel Ned
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of CO5580794A2 publication Critical patent/CO5580794A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

1.- Un conjugado que comprende al menos una molécula polimérica hidrosoluble unida covalentemente a al menos un resto aminoacídico de un polipéptido de hormona de crecimiento humana (hGH) biológicamente activo o una variante agonista de la misma.2.- El conjugado de la reivindicación 1, en el que dicho polipéptido de hGH comprende la secuencia de aminoácidos de la SEC ID N°:1.3.- El conjugado de la reivindicación 1 ó 2, en el que dicho polímero es una molécula de poli(óxido de etileno).4.- El conjugado de la reivindicación 3, en el que dicha molécula de poli(óxido de etileno) es una molécula de poli(etilenglicol).5.- El conjugado de la reivindicación 4, en el que el poli(etilenglicol) está unido a un resto aminoacídico que tiene uno o más grupos amino libres, uno o más grupos carboxilo libres o uno o más grupos sulfhidrilo libres.6.- El conjugado de la reivindicación 5, formado usando un poli(etilenglicol) activado.7.- El conjugado de la reivindicación 6, en el que dicho poli(etilenglicol) activado comprende un grupo funcional.8.- El conjugado de la reivindicación 7, en el que dicha unión se realiza en un aminoácido que tiene un grupo amino libre.9.- El conjugado de la reivindicación 8, en el que dicho grupo funcional se selecciona entre el grupo compuesto por: carbonatos, carbonil imidazol, ésteres activos de ácidos carboxílicos azlactonas, imidationas cíclicas, isocianatos o isotiocianatos, imidatos y aldehídos.10.- El conjugado de la reivindicación 9, en el que dicho grupo funcional es un carbonato o carbonil imidazol.
CO04046633A 2001-11-20 2004-05-20 Conjugados de hormona de crecimiento humana modificada quimicamente CO5580794A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20

Publications (1)

Publication Number Publication Date
CO5580794A2 true CO5580794A2 (es) 2005-11-30

Family

ID=23295870

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04046633A CO5580794A2 (es) 2001-11-20 2004-05-20 Conjugados de hormona de crecimiento humana modificada quimicamente

Country Status (25)

Country Link
EP (1) EP1453859A2 (es)
JP (2) JP2005525302A (es)
KR (2) KR20050044858A (es)
CN (1) CN1608079A (es)
AP (1) AP2004003050A0 (es)
AU (1) AU2002356990A1 (es)
BR (1) BR0214451A (es)
CA (1) CA2467731A1 (es)
CO (1) CO5580794A2 (es)
EA (2) EA200700431A1 (es)
EC (1) ECSP045114A (es)
GE (1) GEP20063860B (es)
HR (1) HRP20040448A2 (es)
HU (1) HUP0500997A2 (es)
IL (1) IL162031A0 (es)
IS (1) IS7268A (es)
MA (1) MA27544A1 (es)
MX (1) MXPA04004809A (es)
NO (1) NO20042182L (es)
OA (1) OA13063A (es)
PL (1) PL374354A1 (es)
RS (1) RS53104A (es)
TN (1) TNSN04090A1 (es)
WO (1) WO2003044056A2 (es)
ZA (1) ZA200403907B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
AU2002357806A1 (en) * 2001-12-11 2003-06-23 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
ME00239B (me) * 2002-01-18 2011-05-10 Biogen Ma Inc Polimerna jedinjenja polialkilena i njihova upotreba
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
ES2897470T3 (es) 2002-09-09 2022-03-01 Nektar Therapeutics Alcanales poliméricos solubles en agua
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
CN100580087C (zh) * 2003-10-10 2010-01-13 诺和诺德医疗保健公司 肽的缀合
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
EP2368579A1 (en) * 2004-01-21 2011-09-28 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
AU2005278903A1 (en) * 2004-08-31 2006-03-09 Pharmacia & Upjohn Company Llc Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
CN103290084A (zh) * 2004-12-22 2013-09-11 Ambrx公司 表达和纯化重组人类生长激素的方法
US7638491B2 (en) 2004-12-22 2009-12-29 Ambrx, Inc. Therapies using non-natural amino acids and polypeptides
CN103690936A (zh) * 2004-12-22 2014-04-02 Ambrx公司 经修饰的人类生长激素
US20090105134A1 (en) 2005-02-10 2009-04-23 Novo Nordisk A/S C-Terminally Pegylated Growth Hormones
EP1877439B1 (en) 2005-04-18 2011-02-09 Novo Nordisk A/S Il-21 variants
US8293708B2 (en) 2005-08-30 2012-10-23 Novo Nordisk Health Care A/G Liquid formulations N-terminal serine of pegylated growth hormone
AU2006311568B2 (en) 2005-11-08 2010-11-11 Ambrx, Inc. Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
US20080317670A1 (en) 2005-12-14 2008-12-25 Ambrx, Inc. Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides
KR20100014215A (ko) 2006-07-07 2010-02-10 노보 노르디스크 헬스 케어 악티엔게젤샤프트 신규 단백질 접합체 및 그것의 제조 방법
CN101108895B (zh) * 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
JP2010507382A (ja) 2006-10-26 2010-03-11 ノヴォ ノルディスク アクティーゼルスカブ Ｉｌ−２１変異体
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
CA2720306C (en) 2008-04-03 2016-03-15 Biosteed Gene Expression Tech. Co., Ltd. Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
KR101104574B1 (ko) * 2008-05-14 2012-01-11 성균관대학교산학협력단 폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도
KR101533757B1 (ko) * 2008-07-31 2015-07-03 파마이센시아 코퍼레이션 펩티드-중합체 접합체
WO2010015668A1 (en) 2008-08-06 2010-02-11 Novo Nordisk A/S Conjugated proteins with prolonged in vivo efficacy
RU2409669C9 (ru) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Способ иммобилизации биологически активного вещества (бав) на носитель (варианты) и конъюгат бав-носитель, полученный данными способами
JP5766118B2 (ja) * 2008-09-11 2015-08-19 ウェルズ ファーゴ バンク ナショナル アソシエイション ポリマー性アルファ−ヒドロキシアルデヒドおよびケトン反応剤ならびに抱合方法
EP2389389B1 (en) 2009-01-22 2015-04-15 Novo Nordisk Health Care AG Stable growth hormone compounds
CN105963710A (zh) 2009-08-06 2016-09-28 诺沃—诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
CN102711733A (zh) 2009-12-15 2012-10-03 阿森迪斯药物股份有限公司 瞬时连接于聚合物载体的干生长激素组合物
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
KR101813595B1 (ko) 2010-01-22 2017-12-29 노보 노르디스크 헬스 케어 악티엔게젤샤프트 장기적 생체 내 효능을 갖는 성장 호르몬
NZ603399A (en) * 2010-05-17 2014-09-26 Cebix Inc Pegylated c-peptide
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (ru) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Ковалентный конъюгат полиэтиленгликоля с гормоном роста человека
EP2981282B1 (en) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Growth hormone compound formulation
WO2016073825A1 (en) 2014-11-06 2016-05-12 Pharmaessentia Corporation Dosage regimen for pegylated interferon
ES2896971T3 (es) 2014-11-21 2022-02-28 Ascendis Pharma Endocrinology Div A/S Formas de administración de hormona del crecimiento de acción prolongada
US20190290733A1 (en) * 2015-03-11 2019-09-26 Nektar Therapeutics Conjugates of an il-7 moiety and a polymer
RU2738416C2 (ru) * 2015-09-18 2020-12-14 Юниверсити Оф Миязаки Длительно действующее производное адреномедуллина
CN114539384A (zh) * 2020-11-19 2022-05-27 江苏众红生物工程创药研究院有限公司 聚乙二醇化长效生长激素及其制备方法和医药应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
ES2113354T3 (es) * 1990-05-04 1998-05-01 American Cyanamid Co Estabilizacion de somatotropinas y otras proteinas por modificacion de residuos de cisteina.
JPH06506217A (ja) * 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE69638117D1 (de) * 1995-09-21 2010-03-04 Genentech Inc Varianten des menschlichen Wachstumshormons
WO1999003887A1 (en) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
IL144259A0 (en) * 1999-01-14 2002-05-23 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
ATE246202T1 (de) * 1999-01-29 2003-08-15 Hoffmann La Roche Gcsf konjugate
AU2001289307A1 (en) * 2000-04-06 2001-10-23 Pharmacia Corporation Chemically-modified myelopoietin conjugates
JP2004524020A (ja) * 2001-01-11 2004-08-12 マキシゲン・エイピーエス 改良された成長ホルモン分子

Also Published As

Publication number Publication date
EA200700431A1 (ru) 2008-02-28
HRP20040448A2 (en) 2006-02-28
PL374354A1 (en) 2005-10-17
KR20070072924A (ko) 2007-07-06
CA2467731A1 (en) 2003-05-30
EA008505B1 (ru) 2007-06-29
BR0214451A (pt) 2006-05-30
TNSN04090A1 (fr) 2006-06-01
MXPA04004809A (es) 2004-08-11
MA27544A1 (fr) 2005-10-03
ZA200403907B (en) 2007-12-27
WO2003044056A2 (en) 2003-05-30
CN1608079A (zh) 2005-04-20
NO20042182L (no) 2004-08-11
JP2005525302A (ja) 2005-08-25
ECSP045114A (es) 2004-07-23
WO2003044056A3 (en) 2003-08-21
OA13063A (en) 2006-11-10
GEP20063860B (en) 2006-06-26
KR20050044858A (ko) 2005-05-13
HUP0500997A2 (en) 2007-11-28
EA200400565A1 (ru) 2005-06-30
AP2004003050A0 (en) 2004-06-30
EP1453859A2 (en) 2004-09-08
JP2006321808A (ja) 2006-11-30
AU2002356990A1 (en) 2003-06-10
IL162031A0 (en) 2005-11-20
IS7268A (is) 2004-05-17
RS53104A (en) 2006-10-27

Similar Documents

Publication Publication Date Title
CO5580794A2 (es) Conjugados de hormona de crecimiento humana modificada quimicamente
AU757658B2 (en) Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
JP2003521937A5 (es)
AR036865A1 (es) Conjugado molecular ionico de poliesteres biodegradables y polipeptidos bioactivos
RU2002120486A (ru) Свободная от агрегатов уратоксидаза для приготовления неиммуногенных полимерных конъюгатов
NZ517012A (en) Peptides that lower blood glucose levels
ATE522563T1 (de) Verzweigte polyalkylenglykole
CA2286575A1 (fr) Compositions presentant une liberation prolongee et leur procede de preparation
ATE424431T2 (de) Verfahren zur herstellung von 1- benzotriazolcarbonatestern von wasserlöslichen polymeren
RU99124209A (ru) Композиции пролонгированного высвобождения и способ их получения
ATE250425T1 (de) Analoga des parathyroid-hormons
EP2711025A3 (en) Self-assembling peptides incorporating modifications and methods of use thereof
RU2001123690A (ru) Ионные молекулярные конъюгаты биодеградируемых сложных полиэфиров и биоактивных полипептидов
AR014621A1 (es) Un poli (etilenglicol) con forma de estrella, heterofuncional, biocompatible, metodo para su obtencion y metodo para conjugarlo con una proteina
EP1763535B1 (de) Mit einem organischem rest verbundenes polypeptid
RU2424246C2 (ru) Способы сайт-специфического пегилирования
DE69736487D1 (de) Peptidzusammensetzung mit wachstumsfaktor-ähnlicher aktivität
DE60236796D1 (de) Verzweigte polyalkylenglykole
CN107519543A (zh) 具有凝血酶响应性的纤溶涂层及其应用
EP2481426B1 (en) Methods for making crosslinked polymers bound to therapeutic agents
FR2846969A1 (fr) Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical
WO2004018697A3 (en) Protease resistant ti-growth hormone releasing hormone
Griffiths et al. Biotransformation of neuropeptides
AU6961601A (en) Transport peptides among which c-terminal E<sup>rns</sup> peptide and analogues thereof
JP2006507328A5 (es)

Legal Events

Date Code Title Description
FC Application refused